BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 18391984)

  • 21. Elevation of c-FLIP in castrate-resistant prostate cancer antagonizes therapeutic response to androgen receptor-targeted therapy.
    McCourt C; Maxwell P; Mazzucchelli R; Montironi R; Scarpelli M; Salto-Tellez M; O'Sullivan JM; Longley DB; Waugh DJ
    Clin Cancer Res; 2012 Jul; 18(14):3822-33. PubMed ID: 22623731
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The sesquiterpene lactone eupatolide sensitizes breast cancer cells to TRAIL through down-regulation of c-FLIP expression.
    Lee J; Hwangbo C; Lee JJ; Seo J; Lee JH
    Oncol Rep; 2010 Jan; 23(1):229-37. PubMed ID: 19956887
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sensitivity of prostate cells to TRAIL-induced apoptosis increases with tumor progression: DR5 and caspase 8 are key players.
    Hesry V; Piquet-Pellorce C; Travert M; Donaghy L; Jégou B; Patard JJ; Guillaudeux T
    Prostate; 2006 Jun; 66(9):987-95. PubMed ID: 16541419
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Programmed cell death 4 (PDCD4) mediates the sensitivity of gastric cancer cells to TRAIL-induced apoptosis by down-regulation of FLIP expression.
    Wang W; Zhao J; Wang H; Sun Y; Peng Z; Zhou G; Fan L; Wang X; Yang S; Wang R; Fang D
    Exp Cell Res; 2010 Sep; 316(15):2456-64. PubMed ID: 20595005
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CK2 controls TRAIL and Fas sensitivity by regulating FLIP levels in endometrial carcinoma cells.
    Llobet D; Eritja N; Encinas M; Llecha N; Yeramian A; Pallares J; Sorolla A; Gonzalez-Tallada FJ; Matias-Guiu X; Dolcet X
    Oncogene; 2008 Apr; 27(18):2513-24. PubMed ID: 17982483
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Regulation of Akt/FOXO3a/GSK-3beta/AR signaling network by isoflavone in prostate cancer cells.
    Li Y; Wang Z; Kong D; Li R; Sarkar SH; Sarkar FH
    J Biol Chem; 2008 Oct; 283(41):27707-27716. PubMed ID: 18687691
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Conditional expression of PTEN alters the androgen responsiveness of prostate cancer cells.
    Wu Z; Conaway M; Gioeli D; Weber MJ; Theodorescu D
    Prostate; 2006 Jul; 66(10):1114-23. PubMed ID: 16637073
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Androgens stimulate hypoxia-inducible factor 1 activation via autocrine loop of tyrosine kinase receptor/phosphatidylinositol 3'-kinase/protein kinase B in prostate cancer cells.
    Mabjeesh NJ; Willard MT; Frederickson CE; Zhong H; Simons JW
    Clin Cancer Res; 2003 Jul; 9(7):2416-25. PubMed ID: 12855613
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Subtoxic concentration of doxorubicin enhances TRAIL-induced apoptosis in human prostate cancer cell line LNCaP.
    Kang J; Bu J; Hao Y; Chen F
    Prostate Cancer Prostatic Dis; 2005; 8(3):274-9. PubMed ID: 15897917
    [TBL] [Abstract][Full Text] [Related]  

  • 30. ErbB1 and prostate cancer: ErbB1 activity is essential for androgen-induced proliferation and protection from the apoptotic effects of LY294002.
    Tørring N; Dagnaes-Hansen F; Sørensen BS; Nexø E; Hynes NE
    Prostate; 2003 Jul; 56(2):142-9. PubMed ID: 12746839
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The proteasome inhibitor PS-341 (bortezomib) up-regulates DR5 expression leading to induction of apoptosis and enhancement of TRAIL-induced apoptosis despite up-regulation of c-FLIP and survivin expression in human NSCLC cells.
    Liu X; Yue P; Chen S; Hu L; Lonial S; Khuri FR; Sun SY
    Cancer Res; 2007 May; 67(10):4981-8. PubMed ID: 17510429
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Overexpression of insulin-like growth factor binding protein-5 helps accelerate progression to androgen-independence in the human prostate LNCaP tumor model through activation of phosphatidylinositol 3'-kinase pathway.
    Miyake H; Nelson C; Rennie PS; Gleave ME
    Endocrinology; 2000 Jun; 141(6):2257-65. PubMed ID: 10830316
    [TBL] [Abstract][Full Text] [Related]  

  • 33. STAMP1 is both a proliferative and an antiapoptotic factor in prostate cancer.
    Wang L; Jin Y; Arnoldussen YJ; Jonson I; Qu S; Maelandsmo GM; Kristian A; Risberg B; Waehre H; Danielsen HE; Saatcioglu F
    Cancer Res; 2010 Jul; 70(14):5818-28. PubMed ID: 20587517
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Malignant ascites protect against TRAIL-induced apoptosis by activating the PI3K/Akt pathway in human ovarian carcinoma cells.
    Lane D; Robert V; Grondin R; Rancourt C; Piché A
    Int J Cancer; 2007 Sep; 121(6):1227-37. PubMed ID: 17534891
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Akt-regulated forkhead transcription factor FOXO3a controls endothelial cell viability through modulation of the caspase-8 inhibitor FLIP.
    Skurk C; Maatz H; Kim HS; Yang J; Abid MR; Aird WC; Walsh K
    J Biol Chem; 2004 Jan; 279(2):1513-25. PubMed ID: 14551207
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Curcumin [1,7-bis(4-hydroxy-3-methoxyphenyl)-1-6-heptadine-3,5-dione; C21H20O6] sensitizes human prostate cancer cells to tumor necrosis factor-related apoptosis-inducing ligand/Apo2L-induced apoptosis by suppressing nuclear factor-kappaB via inhibition of the prosurvival Akt signaling pathway.
    Deeb D; Jiang H; Gao X; Al-Holou S; Danyluk AL; Dulchavsky SA; Gautam SC
    J Pharmacol Exp Ther; 2007 May; 321(2):616-25. PubMed ID: 17289836
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Androgen receptor and prostate apoptosis response factor-4 target the c-FLIP gene to determine survival and apoptosis in the prostate gland.
    Gao S; Wang H; Lee P; Melamed J; Li CX; Zhang F; Wu H; Zhou L; Wang Z
    J Mol Endocrinol; 2006 Jun; 36(3):463-83. PubMed ID: 16720717
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Interruption of nuclear factor kappaB signaling by the androgen receptor facilitates 12-O-tetradecanoylphorbolacetate-induced apoptosis in androgen-sensitive prostate cancer LNCaP cells.
    Altuwaijri S; Lin HK; Chuang KH; Lin WJ; Yeh S; Hanchett LA; Rahman MM; Kang HY; Tsai MY; Zhang Y; Yang L; Chang C
    Cancer Res; 2003 Nov; 63(21):7106-12. PubMed ID: 14612503
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Overcoming resistance to trail-induced apoptosis in prostate cancer by regulation of c-FLIP.
    Zhang X; Li W; Olumi AF
    Methods Enzymol; 2008; 446():333-49. PubMed ID: 18603132
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Role of the phosphatidylinositol 3'-kinase/PTEN/Akt kinase pathway in tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in non-small cell lung cancer cells.
    Kandasamy K; Srivastava RK
    Cancer Res; 2002 Sep; 62(17):4929-37. PubMed ID: 12208743
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.